Susquehanna International Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Susquehanna International Group’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-550	Closed	-$40K	–	14123
2021 Q3	$40K	Sell	550 -2,440	-82%	-$187K	﹤0.01%	12420
2021 Q2	$286K	Buy	+2,990	New	+$330K	﹤0.01%	10870
2018 Q2	–	Sell	-70	Closed	-$6K	–	10622
2018 Q1	$6K	Sell	70 -5	-7%	-$744	﹤0.01%	9194
2017 Q4	$56K	Buy	+75	New	+$29K	﹤0.01%	8885
2016 Q4	–	Sell	-156	Closed	-$177K	–	10306
2016 Q3	$177K	Sell	156 -77	-33%	-$83.1K	﹤0.01%	7674
2016 Q2	$255K	Buy	233 +144	+162%	+$181K	﹤0.01%	7220
2016 Q1	$114K	Sell	89 -307	-78%	-$437K	﹤0.01%	8374
2015 Q4	$972K	Buy	+396	New	+$608K	﹤0.01%	5455
2015 Q2	–	Sell	-564	Closed	-$573K	–	10549
2015 Q1	$573K	Buy	564 +420	+292%	+$1.39M	﹤0.01%	6841
2014 Q4	$479K	Sell	144 -416	-74%	-$1.28M	﹤0.01%	7292
2014 Q3	$1.62M	Buy	560 +377	+206%	+$1.25M	﹤0.01%	5002
2014 Q2	$694K	Buy	+183	New	+$689K	﹤0.01%	6826

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's NBSE Position: Q2 2023 in Review

Susquehanna International Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 963 shares — an estimated $3.56K sold.

Susquehanna International Group first reported a position in NBSE in Q3 2013 and held it in 23 quarters. The position peaked at $759K in Q1 2014. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Susquehanna International Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Susquehanna International Group sold 963 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.56K.
Susquehanna International Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2013 and held it in 23 quarters.
Susquehanna International Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $759K in Q1 2014.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.